1. A DNA methylation-based definition of biologically distinct breast cancer subtypes.

    Molecular Oncology 9(3):555 (2015) PMID 25468711

    In cancer, epigenetic states are deregulated and thought to be of significance in cancer development and progression. We explored DNA methylation-based signatures in association with breast cancer subtypes to assess their impact on clinical presentation and patient prognosis. DNA methylation was...
  2. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.
    Elizabeth K Bancroft, Elizabeth C Page, Elena Castro, Hans Lilja, Andrew Vickers, Daniel Sjoberg, Melissa Assel, Christopher S Foster, Gillian Mitchell, Kate Drew, Lovise Mæhle, Karol Axcrona, D Gareth Evans, Barbara Bulman, Diana Eccles, Donna McBride, Christi van Asperen, Hans Vasen, Lambertus A Kiemeney, Janneke Ringelberg, Cezary Cybulski, Dominika Wokolorczyk, Christina Selkirk, Peter J Hulick, Anders Bojesen, Anne-Bine Skytte, Jimmy Lam, Louise Taylor, Rogier Oldenburg, Ruben Cremers, Gerald Verhaegh, Wendy A van Zelst-Stams, Jan C Oosterwijk, Ignacio Blanco, Monica Salinas, Jackie Cook, Derek J Rosario, Saundra Buys, Tom Conner, Margreet G Ausems, Kai-ren Ong, Jonathan Hoffman, Susan Domchek, Jacquelyn Powers, Manuel R Teixeira, Sofia Maia, William D Foulkes, Nassim Taherian, Marielle Ruijs, Apollonia T Helderman-van den Enden, Louise Izatt, Rosemarie Davidson, Muriel Adank, Lisa Walker, Rita Schmutzler, Kathy Tucker, Judy Kirk, Shirley Hodgson, Marion Harris, Fiona Douglas, Geoffrey J Lindeman, Janez Zgajnar, Marc Tischkowitz, Virginia E Clowes, Rachel Susman, Teresa Ramón y Cajal, Nicholas Patcher, Neus Gadea, Allan Spigelman, Theo van Os, Annelie Liljegren, Lucy Side, Carole Brewer, Angela F Brady, Alan Donaldson, Vigdis Stefansdottir, Eitan Friedman, Rakefet Chen-Shtoyerman, David J Amor, Lucia Copakova, Julian Barwell, Veda N Giri, Vedang Murthy, Nicola Nicolai, Soo-Hwang Teo, Lynn Greenhalgh, Sara Strom, Alex Henderson, John McGrath, David Gallagher, Neil Aaronson, Audrey Ardern-Jones, Chris Bangma, David Dearnaley, Philandra Costello, Jorunn Eyfjord, Jeanette Rothwell, Alison Falconer, Henrik Gronberg, Freddie C Hamdy, Oskar Johannsson, Vincent Khoo, Zsofia Kote-Jarai, Jan Lubinski, Ulrika Axcrona, Jane Melia, Joanne McKinley, Anita V Mitra, Clare Moynihan, Gad Rennert, Mohnish Suri, Penny Wilson, Emma Killick, Sue Moss, and Rosalind A Eeles

    European Urology 66(3):489 (2014) PMID 24484606 PMCID PMC4105321

    Men with germline breast cancer 1, early onset (BRCA1) or breast cancer 2, early onset (BRCA2) gene mutations have a higher risk of developing prostate cancer (PCa) than noncarriers. IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mut...
  3. Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study.

    Cancer Epidemiology Biomarkers & Prevention 16(4):740 (2007) PMID 17416765

    Early menarche and late menopause are important risk factors for breast cancer, but their effects on breast cancer risk in BRCA1 and BRCA2 carriers are unknown. We assessed breast cancer risk in a large series of 1,187 BRCA1 and 414 BRCA2 carriers from the International BRCA1/2 Carrier Cohort St...
  4. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.

    Clinical Cancer Research 12(4):1157 (2006) PMID 16489069

    To investigate the clinical value of somatic TP53 mutations in breast cancer, we assembled clinical and molecular data on 1,794 women with primary breast cancer with long-term follow-up and whose tumor has been screened for mutation in exons 5 to 8 of TP53 by gene sequencing. TP53 mutations were...